GYRE profile · all as-reported value updates
GYRE THERAPEUTICS, INC. (GYRE) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Operating income | 2022 | -8,611,000 | 9,203,000 | 17,814,000 | +193.57% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Net income | 2022 | -8,242,000 | 4,314,000 | 12,556,000 | +152.34% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Stockholders' equity | 2022 | -21,689,000 | 42,522,000 | 64,211,000 | +151.01% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Operating cash flow | 2022 | -33,096,000 | 10,677,000 | 43,773,000 | +132.26% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Assets | 2022 | 28,444,000 | 84,753,000 | 56,309,000 | +66.44% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Liabilities | 2022 | 16,824,000 | 12,536,000 | -4,288,000 | -25.49% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2022 | 21,666,000 | 25,175,000 | 3,509,000 | +13.94% | revised comparative figure | 0001564590-23-004830 0000950170-24-037242 | 2 filed observations examined for this concept and period. |